Trial
NCT05222516
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
OM Pharma SA
Collaborators
—
Condition
Atopic Dermatitis
Intervention
Broncho-Vaxom
Why stopped
Recommendation of DSMB (futility of Endpoints)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-08